ArticleAmerican journal of translational research2025
Efficacy and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma patients.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the therapeutic efficacy and safety profile of the ixazomib-lenalidomide-dexamethasone (IRd) combination in patients with relapsed/refractory multiple myeloma (RRMM).
methodsBetween May 2022 and January 2025, 120 RRMM patients were assigned to a control group (n=52) receiving lenalidomide-dexamethasone (Rd) or an observation group (n=68) treated with IRd. Comparative analyses were conducted to assess therapeutic effectiveness, safety (fatigue, infections, gastrointestinal disturbances, peripheral neuropathy, thrombocytopenia, and leukopenia), bone turnover markers (alkaline phosphatase [ALP], osteocalcin [BGP], C-terminal telopeptide of type I collagen [CTX-I]), inflammatory markers (C-reactive protein [CRP], interleukin-6 [IL-6], tumor necrosis factor-alpha [TNF-α]), and other serum biomarkers (erythrocyte sedimentation rate [ESR], M protein, β
resultsThe observation group demonstrated superior overall effectiveness compared to the control group (P<0.05), without significant differences in adverse event incidence (P>0.05). Post-treatment evaluations showed significantly greater reductions in CTX-I, CRP, IL-6, TNF-α, ESR, M-protein, and β
conclusionsThe IRd regimen demonstrates enhanced clinical efficacy in RRMM management, maintaining a safety profile comparable to the conventional Rd regimen. Furthermore, it effectively improves bone metabolism, reduces serum inflammation, and modulates serum biochemical parameters. Elevated M-protein expression correlates with poorer treatment outcome in RRMM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.